Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care
- 2 August 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , e953-e961
Abstract
Background: Pneumonia causes high rates of hospitalization among adults living in long-term care (LTC) facilities and is a major cause of mortality in this population. Since 2014, pneumococcal conjugate vaccines (PCVs) have been recommended for US adults aged ≥65 years; however, effectiveness of PCVs against all-cause pneumonia hospitalization among adults living in LTC remains unclear. Methods: We used Medicare Fee-for-Service claims data to construct an open cohort of beneficiaries aged ≥65 years between September 2014 and December 2019. We estimated 13-valent PCV (PCV13) vaccine effectiveness (VE) by comparing rates of pneumonia hospitalization among PCV13-exposed and PCV13-unexposed time during LTC stays. Discrete-time logistic regression models with generalized estimating equations were used to estimate VE, incorporating time-varying exposures and covariates. Results: Among 3 485 071 beneficiaries meeting the eligibility criteria, the proportion vaccinated with PCV13 increased from 1.1% to 52.7% during the study period. The characteristics of beneficiaries with shorter LTC stays differed from those with longer LTC stays: a lower proportion of beneficiaries aged ≥85 years (LTC stay ≤100 vs >100 days: 38.5% vs 48.2%), but a higher proportion with chronic medical conditions (71.4% vs 66.4%), immunocompromising conditions (36.6% vs 25.2%), and recent hospitalizations (84.1% vs 74.7%). Vaccine effectiveness of PCV13 only against all-cause pneumonia hospitalization was 3.8% (95% CI 2.4%–5.2%) overall: 5.6% (3.9%–7.2%) for LTC stays ≤100 days and 0.3% (−2.1%–2.77%) for LTC stays >100 days. Conclusions: 13-Valent PCV reduced the risk of pneumonia hospitalization among this population. Differences in beneficiary characteristics could explain differences in VE by length of LTC stay.Keywords
Funding Information
- US Centers for Disease Control and Prevention (GS-10F-0133S:75FCMC21F0067)
- Acumen LLC
This publication has 27 references indexed in Scilit:
- Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017JAMA Internal Medicine, 2023
- Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate VaccineJAMA Network Open, 2022
- Non-ventilator health care-associated pneumonia (NV-HAP): Long-term careAmerican Journal of Infection Control, 2020
- Do-Not-Resuscitate and Do-Not-Hospitalize Orders in Nursing Homes: Who Gets Them and Do They Make a Difference?Journal of the American Medical Directors Association, 2019
- Trends in Post–Acute Care Use Among Medicare Beneficiaries: 2000 to 2015JAMA, 2018
- Predictors of mortality in nursing-home residents with pneumonia: a multicentre studyClinical Microbiology and Infection, 2018
- Bacterial Pneumonia in Older AdultsInfectious Disease Clinics of North America, 2017
- Racial and ethnic disparities in vaccination coverage among adult populations in the U.S.Vaccine, 2015
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsNew England Journal of Medicine, 2015
- Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and preventionThe American Journal of Medicine, 1998